Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the safety, tolerability, and antiviral activity of ANA598 in patients with genotype-1 chronic hepatitis C infection.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Antiviral Agents

Criteria

Inclusion Criteria:

• Male or female, ages 18 to 65 years

• Documented chronic HCV infection, genotype 1a or 1b

• Treatment-naïve

• BMI = 18 - 35 kg/m2

Exclusion Criteria:

• Female patients who are pregnant or breast-feeding

• Previous treatment for HCV infection

• HIV or HBV positive

• Evidence of cirrhosis on previous liver biopsy or on previous imaging studies

• History of any other known cause of liver disease;